Smith+Nephew Prepared to Capitalize on ASC Acceleration

Smith+Nephew's logo

Smith+Nephew reported 2Q20 orthopedic revenue of USD $600.5 million, -33.8% vs. 2Q19. After the market trough in April, the company noted improving trends as restrictions on elective surgeries eased across all regions. China is the first major market to return to growth for Smith+Nephew. U.S. recovery progressed throughout the quarter, with...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us